N1-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-propoxypyrrolidin-2-yl)propan-2-yl)-5-(oxazol-2-yl)-N3,N3-dipropylisophthalamide → N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-propoxypyrrolidin-2-yl)propan-2-yl)-3-((R)-2-(methoxymethyl)pyrrolidine-1-carbonyl)-5-(oxazol-2-yl)benzamide
Reaction equation
[Si](O[C@H]([C@H]1C[C@@H](OCCC)CN1C(OC(C)(C)C)=O)[C@@H](NC(=O)C1C=CC=C(C(OC)=O)C=1)CC1C=C(F)C=C(F)C=1)(C(C)(C)C)(C)C.FC1C=C(C[C@H](NC(=O)C2C=C(C3OC=CN=3)C=C(C(N(CCC)CCC)=O)C=2)[C@H](O)[C@H]2C[C@@H](OCCC)CN2)C=C(F)C=1.[Si]([O:100][C@H:101]([C@H:136]1[CH2:140][C@@H:139]([O:141][CH2:142][CH2:143][CH3:144])[CH2:138][N:137]1C(OC(C)(C)C)=O)[C@@H:102]([NH:112][C:113](=[O:135])[C:114]1[CH:119]=[C:118]([C:120]2[O:121][CH:122]=[CH:123][N:124]=2)[CH:117]=[C:116]([C:125]([N:127]2[CH2:131][CH2:130][CH2:129][C@@H:128]2[CH2:132][O:133][CH3:134])=[O:126])[CH:115]=1)[CH2:103][C:104]1[CH:109]=[C:108]([F:110])[CH:107]=[C:106]([F:111])[CH:105]=1)(C(C)(C)C)(C)C>Cl.O>[F:110][C:108]1[CH:109]=[C:104]([CH2:103][C@H:102]([NH:112][C:113](=[O:135])[C:114]2[CH:119]=[C:118]([C:120]3[O:121][CH:122]=[CH:123][N:124]=3)[CH:117]=[C:116]([C:125]([N:127]3[CH2:131][CH2:130][CH2:129][C@@H:128]3[CH2:132][O:133][CH3:134])=[O:126])[CH:115]=2)[C@H:101]([OH:100])[C@H:136]2[CH2:140][C@@H:139]([O:141][CH2:142][CH2:143][CH3:144])[CH2:138][NH:137]2)[CH:105]=[C:106]([F:111])[CH:107]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 2
Procedure
Step 12 (B): Preparation of N1-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-propoxypyrrolidin-2-yl)propan-2-yl)-5-(oxazol-2-yl)-N3,N3-dipropylisophthalamide. The solution of (2R,4R)-tert-butyl 2-((1S,2S)-2-(3-(benzamido)-5-(oxazol-2-yl)benzamido)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate (step 12 (A), 110 mg) in HCl (4.0 M solution in dioxane, 2 mL) was added 4 drops of H2O and the mixture was stirred at rt for 2 h. The solvent was removed and the mixture was purified by reverse phase HPLC (30×100 mm PHENOMENEX-LUNA S10 column, 42-82% methanol/H2O/0.1% TFA) to give the title compound: 1H NMR (CD3OD, 500 MHz) δ ppm 0.74 (3H, m), 0.97 (3H, m), 1.03 (3H, m), 1.57 (1H, dd, J=5, 15 Hz), 1.63 (1H, m), 1.76 (2H, dd, J=5, 15 Hz), 2.19 (1H, m), 2.54 (1H, m), 2.90 (1H, dd, J=10, 15 Hz), 3.21 (2H, m), 3.35-3.53 (7H, m), 3.85 (1H, m), 4.08 (1H, dd, J=5, 10 Hz), 4.23-4.30 (2H, m), 6.75 (1H, m), 6.92 (2H, m), 7.37 (1H, s), 7.71 (1H, m), 8.06 (1H, s), 8.13 (1H, m), 8.39 (1H, m). MS (ESI) (M+H)+ 613.27.
Workup
- customThe solvent was removed
- customthe mixture was purified by reverse phase HPLC (30×100 mm PHENOMENEX-LUNA S10 column, 42-82% methanol/H2O/0.1% TFA)
Sources & evidence
- ORD record
- ord-15082a47077d4d6382866eb3ecb9b648
- Source dataset
- uspto-grants-2011_07
- Patent number
- US07981913B2
Reaction notes
Loading…